Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06112782 · ClinicalTrials.gov registry record · NA
Keravive by Hydrafacial for Scalp Health and Enhanced Hair Quality
A NA study of Androgenic Alopecia, sponsored by Beauty Health.
- Completed
- Registry status
- NA
- Development phase
- 44
- Enrollment target
- 4
- Study locations
NCT06112782: Completed NA study of Androgenic Alopecia, sponsored by Beauty Health.
NCT06112782 is a NA study of Androgenic Alopecia that has completed, run by Beauty Health. The registered enrollment target is 44 participants, below the 66-participant average among 4 other Androgenic Alopecia trials with a reported enrollment target (33% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06112782, a NA study of Androgenic Alopecia, has completed, sponsored by Beauty Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 44 participants
- Enrollment target
- 4
- Study locations
Study Summary
The study aims to assess the efficacy and safety of Keravive by Hydrafacial treatments and Keravive Peptide Spray for scalp health and enhancing hair quality in patients with androgenic alopecia. This study is intended to be a single arm study. Suitable subjects who meet all inclusion criteria and consented will undergo 3 in-office Keravive by Hydrafacial treatments at Day 0 and Weeks 4 and 8 in combination with daily application on Keravive Peptide Spray at home. Subjects will be assessed at Day 0, and Weeks 4, 8, and 20 by investigators using the Norwood Scale (males), Ludwig Classification (females), and a series of Likert scales for ranking improvement in scalp health and hair quality.
Primary Outcome
Investigator assessments of hair thinning and temporal line recession using Likert scales.
Conditions Studied
Interventions
- DEVICE Keravive by Hydrafacial Treatments
Study Locations (4)
California
- Rebecca Fitzgerald MD Inc - Los Angeles
- Laser & Skin Surgery Medical Group, Inc - Sacramento
- ATS Clinical Research - Santa Monica
Maryland
- Callender Center for Clinical Research - Glenn Dale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2019-07-01 |
| Est. Completion | 2020-01-31 |
| Phase | NA |
What the finished NCT06112782 record still lists
NCT06112782 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 66-participant average among 4 other Androgenic Alopecia trials with a reported enrollment target (33% lower).
The record links to 1 condition, with Androgenic Alopecia appearing as the primary indexed condition, and to 1 intervention - of which Keravive by Hydrafacial Treatments is the first listed.
NCT06112782 reports a single indexed study location in California, Maryland.
Frequently Asked Questions
What is clinical trial NCT06112782 about?
NCT06112782 is a clinical study titled "Keravive by Hydrafacial for Scalp Health and Enhanced Hair Quality". The study aims to assess the efficacy and safety of Keravive by Hydrafacial treatments and Keravive Peptide Spray for scalp health and enhancing hair quality in patients with androgenic alopecia. This study is intended to be a single arm study. Suitable subjects who meet all inclusion criteria and c...
What is the current status of trial NCT06112782?
This trial is currently completed. It is a NA study. The enrollment target is 44 participants. The study started on 2019-07-01. Estimated completion is 2020-01-31.
What conditions does trial NCT06112782 study?
This clinical trial studies the following conditions: Androgenic Alopecia.
What interventions are being tested in trial NCT06112782?
The interventions under investigation include: Keravive by Hydrafacial Treatments (DEVICE).
Who is sponsoring clinical trial NCT06112782?
This trial is sponsored by Beauty Health, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06112782 being conducted?
This trial has 4 study locations across California, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Androgenic Alopecia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Computer-Assisted Hair Restoration Study Using ARTAS System
RECRUITING · NA
-
Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site)
RECRUITING · NA
-
A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Female Subjects With Hair Loss
COMPLETED · NA
-
Follicular Revival in Androgenic Alopecia: Evaluating Use of Micro-needling
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI